 Regenxbio Inc RGNX announced additional interim data from Cohorts 1-3 of Phase 12 trial of RGX-121 for patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II MPS II, Get the Inside Access Traders Are Using to Profit More and Win Bigger. Dont Miss Out on Benzinga Pro! 